Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far, and remember there are only a few more days until the weekend arrives.
So keep plugging away. After all, what are the alternatives?
While you ponder the possibilities, we invite you to join us for a delightful cup of stimulation. Our choice today is maple cinnamon French toast.
Meanwhile, here is the latest menu of tidbits to help you on your way. Have a wonderful day and please do stay in touch.
… Cigna will stop covering GLP-1 weight loss drugs including Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound in its ​employee health plan effective July 1 , Reuters reports. In a document ​circulated to employees on June 1, Cigna suggested those currently using the drug can choose to pay with cash through manufacturer sites or TrumpRx.
The cash-pay purchases will not apply toward a deductible or the amount of ​spending required before enrollees can use their health coverage.
STAT News published a clinical update in Research Highlights on 03 Jun 2026.
The item focuses on STAT+: Pharmalittle: We’re reading about GLP-1 drugs and knees, FDA cell and gene therapy guidance, and more.
Review the original article for the full source wording and details.